Bull case
Incyte is positioned to benefit from a strong mix of durable commercial cash flows and meaningful pipeline optionality, anchored by Jakafi’s growth in myelofibrosis, polycythemia vera, and graft-versus-host disease and supported by pricing power, a constructive partner, and disciplined execution. The dermatology franchise adds a credible long-term offset to future Jakafi pressure, with the topical ruxolitinib program viewed as capable of approaching $0.9B in sales, while Opzelura broadens the company’s reach beyond oncology and reduces concentration risk. Near-term value is also being unlocked by Atebrioz, which brings roughly $205–225M of gross economics, a $25M approval milestone, PRV proceeds that have recently ranged from $195M to $215M, and mid-to-high-single-digit royalties, all against a deep oncology/inflammation pipeline and strong cash generation.